Treatment Resistant Depression Trd Market Size

DelveInsight's "Treatment-Resistant Depression (TRD)—market-2028" report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Treatment-Resistant Depression in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Treatment-Resistant Depression from 2017 to 2028 segmented by seven major markets.

The phenomenon of Treatment-resistant depression (TRD) is described as the occurrence of an inadequate response after adequate treatment with antidepressant agents (in terms of dose, duration, and adherence). It has been broadly defined in the context of major depression disorder (MDD) (unipolar ajor depression), but alternative definitions for bipolar depression have also been suggested.

The European Union's Committee for Human Proprietary Medicinal Products (CHMP) defines TRD as follows: 'A patient is considered therapy-resistant (TRD) when consecutive treatments with two different antidepressant products, used for a sufficient length of time at an adequate dose with adequate affirmation of treatment adherence, fail to induce a clinically meaningful improvement.'


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017-2028


Treatment-Resistant Depression - Disease Understanding and Treatment Algorithm

The classification of TRD in stages has been recently proposed where increasing resistance is equated with an increased failure to respond to antidepressant strategies. The rationale behind this approach is the clinical impression that the greater the degree of treatment resistance, the lower the probability of response to any new treatment. This perspective has yet to be empirically tested, and it is important to keep in mind that all classifications of TRD are not diagnoses per se.

A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated with poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis.


Treatment-Resistant Depression Epidemiology

The Treatment-Resistant Depression epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Age-Specific Prevalence) scenario of Treatment-Resistant Depression in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total prevalent cases of Treatment-Resistant Depression (TRD) in the 7MM was found to be 8,339,329 in 2017. The prevalence of Treatment-Resistant Depression in the 7MM is expected to increase during the study period of 2017-2028.


Treatment-Resistant Depression Drug Chapters

This segment of the Treatment-Resistant Depression report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of TRD in the US is mainly accounted for the management options consisting of pharmacologic treatment options and non-pharmacological therapies.

Pharmacologic treatment options include switching, combination and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants, such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), ?2-antagonists, Agomelatine, Tianeptine are used to treat TRD.

Spravato and Symbyax are the two FDA approved drugs specifically for the treatment of TRD. Other pharmacologic alternatives are also considered for those having an antidepressant action, such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine and in combination with a first-line antidepressant: Lithium, Lamotrigine and second-generation antipsychotics.

Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT). 

Detailed chapters of current therapies, such as Symbyax (olanzapine and fluoxetine hydrochloride) (Eli Lilly and Company), Spravato (Esketamine) (Johnson and Johnson), and emerging therapies, such as ALKS 5461 (Alkermes), AXS-05 (Axsome Therapeutics), Cariprazine (Allergan/Gedeon Richter's), Pimavanserin (Acadia Pharmaceuticals), Seltorexant (JandJ/ Minerva Neurosciences), Esketamine DPI (Celon Pharma), REL-1017 (Relmada Therapeutics), AV-101 (Vistagen therapeutics), and others have also been provided in the report.


Treatment-Resistant Depression Market Outlook

The Treatment-Resistant Depression market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, the market for Treatment-Resistant Depression in 7MM was found to be approximately USD 3,698.34 Million in 2017.

Treatment-Resistant Depression market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Treatment-Resistant Depression treatment market in the US is expected to dominate the market during the forecast period (2019-2028).


Treatment-Resistant Depression Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

The dynamics of Treatment-Resistant Depression market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, AXS-05 (Axsome Therapeutics), ALKS-5461 (Alkermes), Esketamine Nasal Spray (Janssen Pharmaceuticals), Cariprazine (Allergan/ Gedeon Richter), Seltorexant (Minerva Neurosciences), Rapastinel (Naurex), Seltorexant (Minerva Neurosciences), Pimavanserin (Acadia Pharmaceuticals), and AV-101 (VistaGen Therapeutics), and others in the Treatment-Resistant Depression market by 2028.


Treatment-Resistant Depression Report Insights

• Patient Population of Treatment-Resistant Depression

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Treatment-Resistant Depression Report Key Strengths

• 10-Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Treatment-Resistant Depression Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Treatment-Resistant Depression market

• Organize sales and marketing efforts by identifying the best opportunities for Treatment-Resistant Depression market

• To understand the future market competition in the Treatment-Resistant Depression market

1. Key Insights

2. Treatment-Resistant Depression: Market Overview at a Glance

2.1. Market Share (%) Distribution of Treatment-Resistant Depression in 2017

2.2. Market Share (%) Distribution of Treatment-Resistant Depression in 2028

3. Disease Overview: Treatment-Resistant Depression

3.1. Introduction

3.2. Signs and Symptoms

3.3. Causes and Risk factors

3.4. Pathophysiology of depression

3.5. Genetic Basis of Major Depressive Disorder

3.6. Treatment Refractory Depression: Staging

3.7. Diagnosis

3.7.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)

3.7.2. DSM-IV-TR Criteria for Major Depressive Disorder

3.7.3. DSM-IV-TR criteria for severity/psychotic/remission specifiers for current (or most recent) Major Depressive Episode

3.7.4. DSM-V: Diagnostic Criteria - Major depressive disorder

3.7.5. Diagnostic Features

3.7.6. Differential Diagnosis

3.7.7. Diagnostic Criteria of Major Depressive Disorder According to ICD-10

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Diagnosed Prevalent Patient Population of Treatment-Resistant Depression

4.3. Country Wise-Epidemiology of Treatment-Resistant Depression

4.4. United States

4.4.1. Assumptions and Rationale

4.4.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United States

4.4.3. Gender-Specific Cases of Treatment-Resistant Depression in the United States

4.4.4. Age-Specific Cases of Treatment-Resistant Depression in the United States

4.5. EU5

4.5.1. Assumptions and Rationale

4.6. Germany

4.6.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany

4.6.2. Gender-Specific Cases of Treatment-Resistant Depression in Germany

4.6.3. Age-Specific Cases of Treatment-Resistant Depression in Germany

4.7. France

4.7.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France

4.7.2. Gender-Specific Cases of Treatment-Resistant Depression in France

4.7.3. Age-Specific Cases of Treatment-Resistant Depression in France

4.8. Italy

4.8.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy

4.8.2. Gender-Specific Cases of Treatment-Resistant Depression in Italy

4.8.3. Age-Specific Cases of Treatment-Resistant Depression in Italy

4.9. Spain

4.9.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain

4.9.2. Gender-Specific Cases of Treatment-Resistant Depression in Spain

4.9.3. Age-Specific Cases of Treatment-Resistant Depression in Spain

4.10. United Kingdom

4.10.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in United Kingdom

4.10.2. Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom

4.10.3. Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom

4.11. Japan

4.11.1. Assumptions and Rationale

4.11.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan

4.11.3. Gender-Specific Cases of Treatment-Resistant Depression in Japan

4.11.4. Age-Specific Cases of Treatment-Resistant Depression in Japan

5. Current Treatment Practices

5.1. Treatment Strategies for TRD

5.2. NICE guideline: Depression in adults; treatment and management

5.3. French clinical guideline: Treatment Resistance Depression

6. Unmet Needs

7. Marketed drugs

7.1. Symbyax: Eli Lilly and Company

7.1.1. Drug Description

7.1.2. Regulatory Milestones

7.1.3. Safety and Efficacy

7.1.4. Product Profile

7.2. Spravato: Johnson & Johnson

7.2.1. Product Description

7.2.2. Regulatory Milestones

7.2.3. Other Development Activities

7.2.4. Clinical Development

7.2.5. Safety and Efficacy

7.2.6. Product Profile

8. Emerging Therapies

8.1. Key cross competition- Emerging Therapies

8.2. ALKS 5461: Alkermes

8.2.1. Product Description

8.2.2. Other Developmental Activities

8.2.3. Clinical Development

8.2.4. Safety and Efficacy

8.2.5. Product Profile

8.3. AXS-05: Axsome Therapeutics

8.3.1. Drug Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Safety and Efficacy

8.3.5. Product Profile

8.4. Cariprazine: Allergan/Gedeon Richter's

8.4.1. Drug Description

8.4.2. Other Developmental Activities

8.4.3. Clinical Development

8.4.4. Product Profile

8.5. Pimavanserin: ACADIA Pharmaceuticals

8.5.1. Drug Description

8.5.2. Other Developmental Activities

8.5.3. Clinical Development

8.5.4. Safety and Efficacy

8.5.5. Product Profile

8.6. Seltorexant: Johnson and Johnson/Minerva Neurosciences

8.6.1. Drug Description

8.6.2. Other Developmental Activities

8.6.3. Clinical Development

8.6.4. Safety and Efficacy

8.6.5. Product Profile

8.7. Esketamine DPI: Celon Pharma

8.7.1. Drug Description

8.7.2. Clinical Development

8.7.3. Safety and Efficacy

8.7.4. Product Profile

8.8. REL-1017: Relmada Therapeutics

8.8.1. Drug Description

8.8.2. Other Developmental Activities

8.8.3. Clinical Development

8.8.4. Safety and Efficacy

8.8.5. Product Profile

8.9. AV-101: VistaGen therapeutics

8.9.1. Drug Description

8.9.2. Other Developmental Activities

8.9.3. Clinical Development

8.9.4. Safety and Efficacy

8.9.5. Product Profile

9. Other Potential therapies

9.1. Rapastinel: Allergan

9.1.1. Drug Description

9.1.2. Other Developmental Activities

9.1.3. Clinical Development

9.1.4. Safety and Efficacy

9.1.5. Product Profile

9.2. MIJ821: Novartis

9.2.1. Product Description

9.2.2. Other Developmental Activities

9.2.3. Clinical Development

9.2.4. Product Profile

9.3. Psilobycin: COMPASS Pathways

9.3.1. Product Description

9.3.2. Other Developmental Activities

9.3.3. Clinical Development

9.3.4. Safety and Efficacy

9.3.5. Product Profile

10. Treatment-Resistant Depression: 7 Major Market Analysis

10.1. Key Findings

10.2. Market Size of Treatment-Resistant Depression in 7MM

11. Market Outlook by Country

12. The United States: Market Outlook

12.1. United States Market Size

12.1.1. Total Market Size of Treatment-Resistant Depression (TRD)

12.1.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

12.1.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13. EU-5 Countries: Market Outlook

13.1. Germany

13.1.1. Total Market size of Treatment-Resistant Depression (TRD)

13.1.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.1.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13.2. France

13.2.1. Total Market Size of Treatment-Resistant Depression (TRD)

13.2.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.2.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13.3. Italy

13.3.1. Total Market Size of Treatment-Resistant Depression (TRD)

13.3.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.3.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13.4. Spain

13.4.1. Total Market Size of Treatment-Resistant Depression (TRD)

13.4.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.4.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13.5. United Kingdom

13.5.1. Total Market Size of Treatment-Resistant Depression (TRD)

13.5.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.5.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

13.6. Japan: Market Outlook

13.6.1. Total Market Size of Treatment-Resistant Depression (TRD)

13.6.2. Market Size of Treatment-Resistant Depression (TRD) by Current Therapies

13.6.3. Market Size of Treatment-Resistant Depression (TRD) by Emerging Therapies

14. Market Drivers

15. Market Barriers

16. Appendix

16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Table 1: Thase and Rush Staging Method

Table 2: Thase and Rush Staging Method

Table 3: The European Staging Method

Table 4: Massachusetts General Hospital Staging Method

Table 5: Major Depressive Disorder Diagnostic Criteria according to DSM-IV-TR

Table 6: Depressive Episode Criteria (maybe part of Major Depressive Disorder OR an isolated episode)

Table 7: DSM-IV-TR diagnostic criteria - MDD

Table 8: DSM-IV-TR diagnostic criteria for MDD, Single episode

Table 9: DSM-IV-TR diagnostic criteria for MDD, Recurrent

Table 10: Selected DSM-IV-TR Major Depressive Episode Specifier

Table 11: Major depressive disorder diagnostic criteria according to DSM-V

Table 12: Severity/course specifier

Table 13: Prevalent Patient Population of Treatment-Resistant Depression in 7MM (2017-2028)

Table 14: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United States (2017-2028)

Table 15: Gender-Specific Cases of Treatment-Resistant Depression in the United States (2017-2028)

Table 16: Age-Specific Cases of Treatment-Resistant Depression in the United States (2017-2028)

Table 17: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany (2017-2028)

Table 18: Gender-Specific Cases of Treatment-Resistant Depression in Germany (2017-2028)

Table 19: Age-Specific Cases of Treatment-Resistant Depression in Germany (2017-2028)

Table 20: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France (2017-2028)

Table 21: Gender-Specific Cases of Treatment-Resistant Depression in France (2017-2028)

Table 22: Age-Specific Cases of Treatment-Resistant Depression in France (2017-2028)

Table 23: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (2017-2028)

Table 24: Gender-Specific Cases of Treatment-Resistant Depression in Italy (2017-2028)

Table 25: Age-Specific Cases of Treatment-Resistant Depression in Italy (2017-2028)

Table 26: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (2017-2028)

Table 27: Gender-Specific Cases of Treatment-Resistant Depression in Spain (2017-2028)

Table 28: Age-Specific Cases of Treatment-Resistant Depression in Spain (2017-2028)

Table 29: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United Kingdom (2017-2028)

Table 30: Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2028)

Table 31: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2028)

Table 32: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (2017-2028)

Table 33: Gender-Specific Cases of Treatment-Resistant Depression in Japan (2017-2028)

Table 34: Age-Specific Cases of Treatment-Resistant Depression in Japan (2017-2028)

Table 35: Limited response and Treatment-Resistant depression

Table 36: Recommendations for treatment potentiation

Table 37: Esketamine Nasal Spray, Clinical Trial Description, 2019

Table 38: Emerging Drugs Analysis - Key potential therapies

Table 39: Emerging Drugs Analysis - Other potential therapies

Table 40: Emerging Drugs Analysis - Other potential therapies

Table 41: ALKS 5461, Clinical Trial Description, 2018

Table 42: AXS-05, Clinical Trial Description, 2019

Table 43: Cariprazine, Clinical Trial Description, 2019

Table 44 Pimavanserin, Clinical Trial Description, 2019

Table 45: Seltorexant, Clinical Trial Description, 2019

Table 46: Esketamine DPI, Clinical Trial Description, 2019

Table 47: REL-1017, Clinical Trial Description, 2019

Table 48: AV-101, Clinical Trial Description, 2019

Table 49: Rapastinel, Clinical Trial Description, 2019

Table 50: MIN-117, Clinical Trial Description, 2019

Table 51: Clinical Trial Description, 2019

Table 52: Psilobycin, Clinical Trial Description, 2019

Table 53: 7 Major Market Size of Treatment-Resistant Depression in USD Million (2017-2028)

Table 54: United States Market Size of TRD in USD Million (2017-2028)

Table 55: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 56: US TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 57: Germany Market Size of TRD in USD Million (2017-2028)

Table 58: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 59: Germany TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 60: France Market Size of TRD in USD Million (2017-2028)

Table 61: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 62: France TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 63: Italy Market Size of TRD in USD Million (2017-2028)

Table 64: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 65: Italy TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 66: Spain Market Size of TRD in USD Million (2017-2028)

Table 67: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 68: Spain TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 69: United Kingdom Market Size of TRD in USD Million (2017-2028)

Table 70: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 71: UK TRD Market size by Emerging Therapies in USD Million (2017-2028)

Table 72: Japan Market Size of TRD in USD Million (2017-2028)

Table 73: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Table 74: Japan TRD Market size by Emerging Therapies in USD Million (2017-2028)

Figure 1: Signs and Symptoms of Treatment-Resistant Depression

Figure 2: Differential Diagnosis

Figure 3: Total Diagnosed Prevalent Patient Population of TRD in 7MM (2017-2028)

Figure 4: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the US (2017-2028)

Figure 5: Gender-Specific Cases of Treatment-Resistant Depression in the United States (2017-2028)

Figure 6: Age-Specific Cases of Treatment-Resistant Depression in the United States (2017-2028)

Figure 7: Total Diagnosed Prevalent Cases of TRD in Germany (2017-2028)

Figure 8: Gender-Specific Cases of Treatment-Resistant Depression in Germany (2017-2028)

Figure 9: Age-Specific Cases of Treatment-Resistant Depression in Germany (2017-2028)

Figure 10: Total Diagnosed Prevalent Cases of TRD in France (2017-2028)

Figure 11: Gender-Specific Cases of Treatment-Resistant Depression in France (2017-2028)

Figure 12: Age-Specific Cases of Treatment-Resistant Depression in France (2017-2028)

Figure 13: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (2017-2028)

Figure 14: Gender-Specific Cases of Treatment-Resistant Depression in Italy (2017-2028)

Figure 15: Age-Specific Cases of Treatment-Resistant Depression in Italy (2017-2028)

Figure 16: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (2017-2028)

Figure 17: Gender-Specific Cases of Treatment-Resistant Depression in Spain (2017-2028)

Figure 18: Age-Specific Cases of Treatment-Resistant Depression in Spain (2017-2028)

Figure 19: Total Diagnosed Prevalent Cases of TRD in the UK (2017-2028)

Figure 20: Gender-Specific Cases of TRD in the United Kingdom (2017-2028)

Figure 21: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2028)

Figure 22: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (2017-2028)

Figure 23: Gender-Specific Cases of Treatment-Resistant Depression in Japan (2017-2028)

Figure 24: Age-Specific Cases of Treatment-Resistant Depression in Japan (2017-2028)

Figure 25: Recommendations for Switching ADT

Figure 26: Unmet Needs

Figure 27: 7 Major Market Size of Treatment-Resistant Depression in USD Million (2017-2028)

Figure 28: Market Size of TRD in the US, USD Millions (2017-2028)

Figure 29: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 30: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 31: Market Size of TRD in Germany, USD Millions (2017-2028)

Figure 32: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 33: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 34: Market Size of TRD in France USD Millions (2017-2028)

Figure 35: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 36: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 37: Market Size of Treatment-Resistant Depression (TRD) in Italy, USD Millions (2017-2028)

Figure 38: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 39: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 40: Market Size of TRD in Spain, USD Millions (2017-2028)

Figure 41: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 42: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 43: Market Size of TRD in the United Kingdom, USD Millions (2017-2028)

Figure 44: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 45: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 46: Market Size of Treatment-Resistant Depression in Japan, USD Millions (2017-2028)

Figure 47: Market Size of TRD by Current Therapies in USD Million (2017-2028)

Figure 48: Market Size of TRD by Emerging Therapies in USD Million (2017-2028)

Figure 49: Market Drivers

Figure 50: Market Barriers

  • Tags:
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TRD...
  • Treatment-Resistant Depression (TR...

Forward to Friend

Need A Quote